Ceftobiprole and its Impurities

Ceftobiprole is the first cephalosporin to demonstrate clinical efficacy in patients with infections due to methicillin-resistant staphylococci and, if approved by regulatory authorities, is expected to be a useful addition to the armamentarium of agents for the treatment of complicated skin infections and pneumonia. Reference standards of Ceftobiprole API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.